PACIFIC phase III trial data at ESMO showed an estimated 35% of non-small cell lung cancer patients treated with Imfinzi had not progressed after four years.- AstraZeneca
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest